National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (as fumarate)(Stribild®)

Indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over who are antiretroviral treatment-naïve or are infected with HIV-1 without known mutations associated with resistance to the three antiretroviral agents in Stribild®.

Rapid Review 

Commenced Completed Outcome
28/04/2013 17/05/2013 Full Pharmacoeconomic Evaluation Recommended


06/12/2013 Following commercial discussions with Gilead, the HSE has approved hospital pricing of Stribild.